Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies

SIMPLE SUMMARY: Approved chimeric antigen receptor (CAR) T cells recognize and bind to only one tumor target (single-targeted CAR T cells, Si-CART) on cancer cells by the special receptor and followed with activation, thus removing cancers from patients. However, cancer cells can resist the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Bailu, Li, Zhengdong, Zhou, Jianfeng, Wang, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265066/
https://www.ncbi.nlm.nih.gov/pubmed/35805001
http://dx.doi.org/10.3390/cancers14133230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265066/
https://www.ncbi.nlm.nih.gov/pubmed/35805001
http://dx.doi.org/10.3390/cancers14133230

Ejemplares similares